142 related articles for article (PubMed ID: 36087071)
21. Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma.
Yan C; Richard MA; Gibson CJ; He J; Bosworth A; Crossman DK; Singh P; Hageman L; Kalra R; Armenian SH; Vose J; Weisdorf DJ; Ebert BL; Yasui Y; Forman SJ; Bhatia R; Bhatia S
J Clin Oncol; 2024 Apr; ():JCO2302547. PubMed ID: 38635938
[TBL] [Abstract][Full Text] [Related]
22. Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.
Slavin TP; Teh JB; Weitzel JN; Peng K; Wong FL; Qin H; Wang J; Wu X; Mei M; Pillai R; Wang Y; Tsang KK; Pozhitkov A; Krishnan A; Forman SJ; Armenian SH
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2517-2521. PubMed ID: 31445185
[TBL] [Abstract][Full Text] [Related]
23. Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML.
Heini AD; Porret N; Zenhaeusern R; Winkler A; Bacher U; Pabst T
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202404
[TBL] [Abstract][Full Text] [Related]
24. Clonal hematopoiesis in the setting of hematopoietic cell transplantation.
Gibson CJ; Lindsley RC; Gondek LP
Semin Hematol; 2024 Feb; 61(1):9-15. PubMed ID: 38429201
[TBL] [Abstract][Full Text] [Related]
25. Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
Newell LF; Williams T; Liu J; Yu Y; Chen Y; Booth GC; Knight RJ; Goslee KR; Cook RJ; Leonard J; Meyers G; Traer E; Press RD; Fan G; Wang Y; Raess PW; Maziarz RT; Dunlap J
Transplant Cell Ther; 2021 Aug; 27(8):662.e1-662.e9. PubMed ID: 33901720
[TBL] [Abstract][Full Text] [Related]
26. Herpes zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation.
Abbasov E; Metzner B; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voß A; Köhne CH
Eur J Haematol; 2022 Sep; 109(3):298-304. PubMed ID: 35687019
[TBL] [Abstract][Full Text] [Related]
27. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
28. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
29. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
Oran B; Champlin RE; Wang F; Tanaka T; Saliba RM; Al-Atrash G; Garcia-Manero G; Kantarjian H; Cao K; Shpall EJ; Alousi AM; Mehta RS; Popat U; Futreal A; Takahashi K
Leukemia; 2022 Jan; 36(1):257-262. PubMed ID: 34135465
[TBL] [Abstract][Full Text] [Related]
30. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
Bento L; Boumendil A; Finel H; Khvedelidze I; Blaise D; Fegueux N; Castagna L; Forcade E; Chevallier P; Mordini N; Brice P; Deconinck E; Gramatzki M; Corradini P; Hunault M; Musso M; Tsoulkani A; Caballero D; Nati S; Montoto S; Sureda A;
Bone Marrow Transplant; 2021 Mar; 56(3):655-663. PubMed ID: 33046830
[TBL] [Abstract][Full Text] [Related]
31. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
33. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
34. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
35. The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.
Nawas MT; Schetelig J; Damm F; Levine RL; Perales MA; Giralt SA; VanDenBrink MR; Arcila ME; Zehir A; Papaemmanuil E; Klussmeier A; Schmidt AH; Maiwald S; Bolton KL; Tamari R
Blood Rev; 2021 Mar; 46():100744. PubMed ID: 32896435
[TBL] [Abstract][Full Text] [Related]
36. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
[TBL] [Abstract][Full Text] [Related]
37. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
[TBL] [Abstract][Full Text] [Related]
39. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
